Research progress on the antitumor effects of nuclear export protein 1 inhibitors and combined medication strategies
10.11665/j.issn.1000-5048.2025121702
- VernacularTitle:核输出蛋白1抑制剂的抗肿瘤作用及联合用药策略研究进展
- Author:
Fangrong SHI
1
;
Jialiang LU
;
Tao LEI
;
Jinxin CHE
;
Haiyan YANG
;
Jianjun LI
Author Information
1. 浙江工业大学全省化学药绿色制造技术重点实验室, 杭州310014;浙江大学药学院药物发现与设计研究所, 杭州310058;浙江省肿瘤医院, 杭州310022
- Publication Type:Journal Article
- Keywords:
XPO1;
drug resistance mechanism;
combination therapy;
tumor signaling pathway
- From:
Journal of China Pharmaceutical University
2026;57(3):385-392
- CountryChina
- Language:Chinese
-
Abstract:
Exportin 1 (XPO1) is aberrantly overexpressed in various malignant tumors and can lead to the loss of anti-tumor effects of important tumor suppressor proteins such as p53, RB1, and FOXO by mediating their nuclear export. Although XPO1 inhibitor Selinexor has entered clinical application, its single-agent anti-tumor activity remains suboptimal, which is closely related to the compensatory activation of multiple signaling pathways in response to XPO1 inhibition. Focusing on the core regulatory role of XPO1 in tumor cells, this article systematically summarizes the current landscape of combination therapies involving XPO1 inhibitors and various targeted agents, including inhibitors of CDK4/6, FLT3, BET, ATR, and BCL2/MDM2, aiming to provide some reference for the development of XPO1-centered combination therapy strategies.
